Table 1.
Information of EOMG patients.
| Patient* | Sex | MG grade | Age at MG onset (yrs) | MG duration at thymectomy (yrs) | Anti-AChR (nM) |
|---|---|---|---|---|---|
|
| |||||
| MG-1 | F | 2A | 20 | 2.5 | >730 |
| MG-2 | F | 3 | 16 | 0.6 | 180 |
| MG-3 | F | 3 | 24 | 0.4 | 252 |
| MG-4 | F | 2B | 39 | 1.8 | 71 |
| MG-5 | F | 2A | 30 | 1.9 | 156 |
| MG-6 | F | 2B | 21 | 0.7 | 72 |
| MG-7 | F | 2A | 34 | 0.5 | 79 |
| MG-8 | F | 2A | 25 | 13.8 | 500 |
| MG-9 | M | 2B | 36 | 0.8 | 23 |
| MG-10 | F | 2A | 20 | 0.7 | >500 |
*
MG-1 - MG-9 were thymectomized in London (UK) and their thymic cell suspensions stored in liquid nitrogen at the Neuroscience Group Biobank, Oxford University; MG-10 was thymectomized in Maastricht (the Netherlands) and her cells were tested fresh. None of the patients received immunosuppressive drugs before thymectomy and all thymi showed follicular hyperplasia.